HYPERION DEFI, INC. annual report, FY2019

Business context and reporting period

Filing identity: The supplied filing is Eyenovia, Inc.’s Form 10-K, not a filing for HYPERION DEFI, INC. Eyenovia (Nasdaq: EYEN) reported for the fiscal year ended December 31, 2019; the financial comparisons are with 2018.

Eyenovia is a clinical-stage ophthalmic biopharmaceutical company developing microdose eye treatments using its Optejet piezo-print delivery technology. It had no approved products or product sales during the period.

Financial results and liquidity

Working capital was $11.4 million and stockholders’ equity was $11.7 million at December 31, 2019. With no revenue, operating margins are not meaningful. The filing reports an accumulated deficit of $57.7 million.

Material changes versus 2018

• Net loss increased by about $3.9 million; R&D spending rose 27% and G&A spending rose 17%, reflecting expanded development activity, staffing and public-company costs.
• Operating cash use increased by about $5.8 million. Cash declined by about $5.6 million despite $13.5 million of financing cash inflows, primarily from the July 2019 public offering.
• Common shares outstanding at year-end rose to 17.1 million from 11.5 million, principally reflecting the 2019 offering and option exercises.
• The company prioritized MicroLine alongside MicroPine and MicroStat, deferring MicroProst and MicroTears. Management estimated this reprioritization could save $1.5–$1.9 million in 2020.

Outlook, commentary and risks

• Going concern: The auditor’s report and management disclosures state that substantial doubt exists about Eyenovia’s ability to continue as a going concern without additional funding. Management said available cash was not sufficient to support operations for at least one year from issuance of the financial statements.
• Development milestones: Management planned to initiate and complete MicroLine Phase III VISION trials, complete MicroPine CHAPERONE enrollment, and submit a MicroStat NDA in 2020. These are forward-looking plans, not completed outcomes in this filing.
• Clinical evidence: MicroStat’s two Phase III studies met their primary objectives, with positive dilation results and few reported adverse events. MicroPine’s Phase III trial began enrolling in 2019; its primary efficacy assessment is after three years of treatment.
• Financing after year-end: On March 24, 2020, Eyenovia closed a private placement raising approximately $5.3 million net, issuing 2.68 million common shares and warrants. This funding does not remove the development, spending or future-financing risks described in the filing.
• Key risks: The company has no product revenue and expects continued losses; clinical trial timing, enrollment and results are uncertain; FDA approval and commercialization are not assured; and manufacturing relies on third parties without long-term supply agreements. The filing also cites potential COVID-19 effects on clinical enrollment, operations and markets.
• Other matters: The company reported no legal proceedings in Item 3; the notes describe a 2018 settlement of a prior shareholder claim, to which Eyenovia contributed $150,000. Management reported effective disclosure controls and internal control over financial reporting at year-end 2019.

Important facts for investors to verify

1. Confirm the issuer identity: this source is Eyenovia, Inc. (EYEN), not HYPERION DEFI, INC.
2. Review the detailed cash runway and financing needs, including the effect of the March 2020 placement and subsequent spending.
3. Check actual progress and results for the planned MicroLine and MicroPine trials and the MicroStat NDA submission against the stated 2020 milestones.
4. Assess potential dilution from shares and warrants issued in the March 2020 placement, as well as future capital raises.
5. Evaluate whether manufacturing capacity, supplier arrangements and regulatory requirements can support clinical completion and any eventual launch.